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A B S T R A C T
Background and objectives: Current tools struggle to detect drug-resistant malaria parasites when
infections contain multiple parasite clones, which is the norm in high transmission settings in Africa.
Our aim was to develop and apply an approach for detecting resistance that overcomes the challenges
of polyclonal infections without requiring a genetic marker for resistance.
Methodology: Clinical samples from patients treated with artemisinin combination therapy were col-
lected from Tanzania and Cambodia. By deeply sequencing a hypervariable locus, we quantified the
relative abundance of parasite subpopulations (defined by haplotypes of that locus) within infections
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and revealed evolutionary dynamics during treatment. Slow clearance is a phenotypic, clinical marker of
artemisinin resistance; we analyzed variation in clearance rates within infections by fitting parasite
clearance curves to subpopulation data.
Results: In Tanzania, we found substantial variation in clearance rates within individual patients. Some
parasite subpopulations cleared as slowly as resistant parasites observed in Cambodia. We evaluated
possible explanations for these data, including resistance to drugs. Assuming slow clearance was a
stable phenotype of subpopulations, simulations predicted that modest increases in their frequency
could substantially increase time to cure.
Conclusions and implications: By characterizing parasite subpopulations within patients, our method
can detect rare, slow clearing parasites in vivo whose phenotypic effects would otherwise be masked.
Since our approach can be applied to polyclonal infections even when the genetics underlying resistance
are unknown, it could aid in monitoring the emergence of artemisinin resistance. Our application to
Tanzanian samples uncovers rare subpopulations with worrying phenotypes for closer examination.
K E Y W O R D S : malaria; within-host selection; ecology; amplicon sequencing; artemisinin; drug
resistance
INTRODUCTION
The emergence of drug-resistant malaria parasites is a
major hurdle in the control of Plasmodium falciparum,
which has evolved resistance to nearly every antimal-
arial drug in use [1]. A major concern is the emergence
in South East Asia of resistance to the current front-
line artemisinin derivatives [2–6], which could spark a
global health crisis. To maximize the continued effi-
cacy of these drugs, early detection of resistance, good
surveillance and containment are required.
Drug resistance in P. falciparum may be moni-
tored using three tools: (i) therapeutic efficacy tests,
(ii) in vitro susceptibility tests and (iii) molecular
markers that are linked to the determinants of resist-
ance. Each of these approaches has advantages and
limitations [7]. For artemisinin resistance, signifi-
cant advances in these areas have been made over
the last several years, with a strong molecular cor-
relate for resistance identified in Asia [8] and in vitro
sensitivity assays developed [9]. The polymorphisms
in a gene (kelch13) associated with artemisinin re-
sistance in Asia have been observed in Africa [10, 11],
though their associated phenotypes in African
parasites have not yet been identified. Molecular
assays are complicated by the fact that the resistance
phenotype associated with some K13 mutations de-
pends on the genetic background in which they
occur, suggesting a multi-gene trait [12], and there
is evidence that compensatory mutations may be
important for the selection and spread of these mu-
tations [13]. Finally, there may be alternate pathways
to artemisinin resistance, as was observed for resist-
ance to chloroquine [14], so the genetic signature of
any artemisinin-resistant parasites that emerge in
Africa may be different than what is emerging in
Southeast Asia (as suggested by recent data [15–
17]). Thus, phenotypic data—either in vivo or in
vitro—is still required for detecting resistance to ar-
temisinin [18].
The current clinical tool for phenotyping parasites
and monitoring therapeutic efficacy of artemisinin is
the parasite clearance curve, which tracks the de-
cline in total parasite density over the course of treat-
ment [19, 20]. Infections that have slower clearance
times (longer half-lives) are regarded as harboring
more resistant parasites [2–4]. However, parasite
clearance curves are less informative in regions with
relatively high complexity of infection (i.e. many
parasite clones or strains within a host) since the
parasite clearance curve is a whole-infection level
measure that represents a weighted average of the
clearance phenotypes of different parasites within
that sample [7]. Recent work in Southeast Asia,
where artemisinin resistance is emerging, has
shown individual infections harboring parasites with
different and stable clearance phenotypes [21]. In
Africa, the majority of falciparum malaria infections
are polyclonal [22] meaning that resistant parasites
are likely to share their host with sensitive parasites
[23–26], particularly during the early spread of drug
resistance. When resistance is rare, the effects of
slow clearing clones on infection-level estimates of
resistance are likely to be obscured by the sheer
number of faster-clearing, sensitive parasites in an
infection (Fig. 1) [7]. Understanding the conse-
quences of drug treatment on the within-host evolu-
tionary dynamics of malaria infections in Africa is
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critical for understanding the risks of artemisinin
resistance emerging.
To overcome the challenges imposed by polyclonal
infections, we previously proposed an approach that
capitalizes on second generation sequencing to re-
veal phenotypic signatures of resistance by partition-
ing an infection into subpopulations of parasites [7].
Our approach characterizes and quantifies the rela-
tive abundance of subpopulations by sequencing a
highly polymorphic region to define haplotypes and
their frequencies over the course of drug treatment [7,
11, 22, 25, 27]. A subpopulation may represent one or
multiple clones (genetically identical parasites that
can only be truly defined by extensive whole-genome
sequencing of individual parasites) and while these
subpopulations may still be composed of phenotyp-
ically variable parasites, they offer considerably higher
resolution than whole-infection measures of clear-
ance phenotypes. The number of haplotypes we de-
tect [22] is on par with clone estimates from whole-
genome sequencing [28] and currently exceeds other
genotyping methods in similar parasite populations
[25]. Importantly, identifying drug-resistant haplo-
types using this approach does not require genetic
linkage (or physical proximity) of the chosen marker
to the genetic determinant of resistance. Instead, our
approach makes it possible to detect whether para-
sites with the resistance phenotype, i.e. slow clear-
ance, are present in infections with sensitive
parasites because subpopulations composed of pre-
dominately resistant clones will increase in relative
abundance as drug treatment is applied (Fig. 1). It
also allows for post hoc genetic work, by identifying
slower clearing subpopulations that demand further
study.
We now apply and refine our approach by
investigating the clearance phenotypes of parasite
subpopulations longitudinally through the ini-
tial days of drug treatment from two populations: (i)
Cambodian participants treated with dihydroar-
temisinin-piperaquine (DHA-Pip) with parasite clear-
ance times of 72 h or greater by microscopy and (ii)
Tanzanian participants treated with artemether-
lumefantrine (AL) with parasite clearance times less
than 72 h by microscopy but polymerase chain reac-
tion (PCR)-detectable residual parasitemia up to 72 h.
We deep sequenced the region of the P. falciparum
circumsporozoite protein gene (pfcsp) encoding the
polymorphic C-terminal region, generating haplotypes
that defined the subpopulations, which were
quantified and tracked during the course of infection.
Though this is an immunogenic antigen, this gene is
not expressed by parasites in the erythrocytic stage
that we are studying, which helps minimize the impact
anti-csp immunity may play on clearance rates. We
show that within complex falciparum infections in
Tanzania, pfcsp subpopulations demonstrate signifi-
cant variation in their response to artemisinin-
combination therapies (ACTs) and that some
subpopulations clear at rates as slow as those of arte-
misinin-resistant parasites in Cambodia. We also find
that the slowest clearing subpopulations sampled in
Tanzania do not contain polymorphisms in the gene
associated with artemisinin resistance in Southeast
Asia [8].
METHODOLOGY
Ethics statement
The trials from which clinical specimens were used were
reviewed by ethics boards of the National Institute for
Medical Research, Dar es Salaam, Tanzania; Regional
Ethics Committee, Stockholm, Sweden; Walter Reed
Army Institute of Research; National Ethics
Committee for Health Research in Cambodia and
University of North Carolina [29, 30].
Study participants
Cambodian samples were taken from an in vivo effi-
cacy study of DHA-Pip [29]. This trial was registered
with the ClinicalTrials.gov identifier NCT01280162.
Samples from all participants with clearance times
of 72 h or greater by microscopy (seven patients)
were used. Tanzanian samples were selected from
ones obtained from 50 children with uncomplicated
falciparum malaria from Fukayosi, Bagamoyo
District, Tanzania, that were enrolled in a trial of
AL in 2006 [30]. Samples from all participants who
remained PCR positive at 72 h (seven patients) were
used. In addition, samples from patients who
cleared (i.e. were PCR negative) after 48 h (seven
patients) and a subset of samples from patients
who cleared after 24 h (5 patients) were included.
Sequencing of pfcsp
Genomic DNA was extracted from filter paper blood
spots using an Invitrogen Pure-link 96-well Genomic
DNA extraction kit (Invitrogen, Carlsbad, CA).
The C-terminal region of the gene pfcsp was
amplified using primers previously described [22],
with a minor modification. The samples were
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amplified using a sample-specific forward primer
indexed with a barcode, based on published
molecular identifier (MID) sequences from Roche,
and a universal non-indexed reverse primer. All sam-
ples were amplified and sequenced in duplicate. The
PCR was carried out using 300 nm of each primer
using Q5 HiFidelity polymerase (New England
Biolabs, Ipswich, MA) under the conditions previ-
ously published [22]. Each sample was amplified in
duplicate, and equimolar amounts of each barcoded
PCR product (after 35 cycles) were mixed. These
libraries were prepared for sequencing on an Ion
Torrent PGM at the UNC Microbiome Core Facility
using the Ion Plus Fragment kit (Life Technologies,
Foster City, CA) and IonExpress Index Barcodes.
Equimolar amounts of each library were pooled
and sequenced using the 400-bp sequencing kit. By
incorporating two barcodes, one in the PCR and one
in the library preparation, we can highly multiplex the
sequencing of amplicons (Fig. 2). Sequence reads
were demultiplexed and clustered using an in-house
script, SeekDeep, as previously described [31]
(http://baileylab.umassmed.edu/SeekDeep).
Haplotypes were kept if they occurred in both dupli-
cate sequencing reactions and were above an
averaged frequency cutoff of 0.5% (i.e. if the average
frequency across duplicate runs was above this
cutoff). This was the default cutoff; however, we
defined parasite density-specific cutoffs to account
for the fact that sequencing is more error prone when
parasite density is lower by generating a dilution ser-
ies of control mixtures (described below). For each
sample (patient and time point), we defined a
unique average frequency cutoff, dependent on the
parasite density in that sample.
Quantification of parasitemias
The quantification of parasite DNA in all extracted
samples was done using a Biorad QX200 digital
droplet PCR system (BioRad, Hercules, CA)
allowing for absolute quantification of parasit-
emias in the extracted DNA [32]. Primers and
probes for PgMet were adapted from previous re-
ports [33]. The assay was completed using primers
at a concentration of 300 nM and probe at a con-
centration of 200 nM using the ddPCR Supermix
for probes.
Control mixtures and sequencing dilution
series
Stocks of malaria DNA from MR4 were quantified
using a previously described real-time PCR assay
Figure 1. Clearance curves and determination of ‘clones’ by deep sequencing. Predicted relative abundances (A) and clearance
curves (B) for hypothetical infections composed of sensitive (black, 3-h half-life) and resistant (gray, 6.5-h half life) parasite clones
after drug treatment. The initial frequency of the resistant clone is 25% in the top row and 1% in the bottom row. In (B), the dotted
line shows the standard parasite clearance curve, as fitted to the total parasite density. The half-life estimates from these curves,
for the whole infection, are 5.5 h (top) and 4 h (bottom). When the resistant clone is rare it exerts little effect on the overall
estimate of parasite half-life
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[34]. A mixture was created using stocks with three
different pfcsp genotypes in the region amplified for
deep sequencing. This control DNA was mixed with
human DNA to reach a final concentration of 1 ng/
ml. The sample was then diluted 1:2 using human
DNA to maintain the final total concentration of
1 ng/ml while reducing the amount of malaria
DNA in the sample. Parasite density is expressed
as genome equivalents (GE) per microliter,
calculated using the approximate genome size of
23 Mb and an average base pair weight of 650
Daltons. This provided control samples ranging
from 1536 to 3 GE/ml. Each sample in the dilution
series was then amplified using 6 MID labeled pri-
mers. PCR fragments were library prepped as pre-
viously described.
To confirm the contents of the mixture, the PCR
product from one of the mixtures was cloned into a
pCR4-TOPO plasmid using the TOPO TA Cloning Kit
for Sequencing (Invitrogen). Colonies were picked
and plasmids harvested using the Zyppy-96
Plasmid Miniprep (Zymo Research) and cloned frag-
ments were Sanger Sequenced at Eton Biosciences
(RTP, NC). Parasite density-specific frequency
cutoffs were determined by plotting the parasite
density of control mixtures versus the frequency of
false haplotypes observed in those mixtures. We
fitted a non-linear curve to this data and used the
fitted curve to predict the frequency below which
calling haplotypes would be suspect, for a given in-
put density. See Supplementary Material for fitted
curve and further details.
Sequencing of the K13-propeller domain
We used a hemi-nested protocol to amplify nucleo-
tides 1279–2030 of PF3D7_1343700, corresponding
to the K13-propeller domain as previously described
[11]. Products were electrophoresed on 2% agarose
gels to confirm products. PCR products were
cleaned with the Invitrogen PureLink kit (Life
Technologies, Carlsbad, CA), and these were bi-dir-
ectionally sequenced using ABI BigDye Terminator
chemistry at Eton Bioscience (San Diego, CA).
Reads were aligned to reference PF3d7_1343700
(www.plasmodb.org; 11 January 2016, date last
accessed) and scored for polymorphisms.
Genetic variation in clearance curves
Clearance curves for individual parasite
subpopulations (as defined by haplotypes) were
produced by multiplying total parasitemia
(quantified by PCR) by the relative abundance of
those subpopulations (quantified by amplicon
sequencing). This generated two density estimates
for each subpopulation at each time point since
there were technical replicates at the PCR and
sequencing stages, with DNA extracted from a sin-
gle blood spot. For each patient that was sampled at
a minimum of two time points, we fitted two linear
models to the subpopulation-specific decline in loge
parasitemia over time (using the lm function in R,
version 3.0.2; http://www.R-project.org). Model 1
included subpopulation as a fixed factor, as well as
an interaction between subpopulation and time,
allowing for unique slopes and intercepts for each
subpopulation. Model 2 included subpopulation as
a fixed factor but no interaction term. By allowing for
unique intercepts, but a single clearance slope,
Model 2 assumes that all subpopulations are cleared
from the infection at the same rate, i.e. are equally
sensitive to drug treatment. Included in these ana-
lyses were only those subpopulations that occurred
at time 0 and were sufficiently abundant to be
captured by sequencing in at least one other time
point (there are no fitted lines for some of the
subpopulations). We did this to avoid making arbi-
trary assumptions about the initial frequency of
subpopulations that emerged later. Additionally,
we suggest that this will provide a conservative es-
timate of resistance within a host, as any initially
undetectable subpopulation that emerges at later
time points likely has an even slower clearance rate
than those we do estimate.
For each patient, we compared the change in de-
viance between Model 1 and Model 2 to F distribu-
tions. Degrees of freedom correspond to the
difference in the number of terms in the model rela-
tive to the residual degrees of freedom. Significant
changes in deviance indicate that the more
complicated model (Model 1) provides a better fit
to the data and therefore demonstrates significant
variation in clearance rates. We found significant
temporal autocorrelation within two of the individ-
ual datasets (T01,P = 0.025; T47,P = 0.0002), so we
reran these analyses using Generalized Least
Squares models, incorporating a corAR1 autocorrel-
ation structure in the fitted models [35, 36].
Statistical analyses were performed using R version
3.0.2. Only results from patients who were PCR posi-
tive at 72 h post-drug treatment are included in the
main text. Similar analyses and results are presented
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in the Supplementary Material for patients who were
PCR negative at or before 72 h post-drug treatment.
Estimating biological significance of variation
in clearance curves
To determine whether the level of variation in clear-
ance rates observed is biologically important, we
simulated infections with two clearance phenotypes
to see how changing the frequency of slow clearing
parasites would affect time to clearance. For each of
the six patients presented in the main text for whom
we found significant variation in clearance rates, we
simulated infections with the same initial parasit-
emia as was measured for that patient at time 0 in
the clinic. These parasites were divided into two
MID
Forward
Reverse
MID
MID
MID
MID
MID
MID
MID
MID
MID
MID
MID
MID
MID
MID
MID
MID
MID
MID
MID
MID
MID
Mix Additional MID
Coded PCR Products
Ion Torrent Indexed Fragment Library Preparation
Final Multiplexed Library
Mix Additional Indexed
Fragment Libraries
A
B
C
Figure 2. Schematic of library preparation for highly multiplexed amplicon deep sequencing. (A) Samples are amplified using
primers targeting conserved sequences (black fragments) surrounding variable regions (colored fragments). The forward primer
contains a barcode (MID) specific to the sample and replicate. (B) After amplification, each PCR reaction contains amplicons
representing the haplotypes within that sample labeled with the specific MID. (C) Multiple samples are then mixed forming a final
library containing multiple MIDs (white, blue, purple and brown) for preparation for sequencing. This mixture is library prepped
with a specific index placed on the library during the process. Multiple libraries with different indexes can then be pooled and
sequenced at the same time allowing for highly multiplexed sequencing
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phenotypes: one clearing at a rate estimated directly
from fitting a linear model to the loge parasitemia
measured by PCR (i.e. the weighted average clear-
ance rate of the whole infection, as would be
estimated by the Parasite Clearance Curve
Estimator, www.wwarn.org/pce/) [19] and one clear-
ing at a rate given by the shallowest slope estimated
for any subpopulation in that infection (i.e. the
slowest clearing subpopulation). Assuming the
same log-linear decline due to drugs, the loge density
of parasites with phenotype i (slow clearing or aver-
age) at time t in hours, Pi,t, is given by
Pi;t ¼ log fiD0
 þmit;
where fi is the initial frequency of parasites with
phenotype i, D0 is the initial (unlogged) total para-
site density andmi is the clearance rate of phenotype
i. Total parasite density at time t, Dt, is given by
Dt ¼ fSD0emSt þ 1 fS
 
D0e
mAt;
where the S and A subscripts indicate either a slow
clearing or average phenotype, respectively. For a
given frequency of the slow clearing phenotype, fS,
we simulated total parasite density over many hours
(max. 3000) and determined the time at which the
infection was reduced to a density of 1 parasite gen-
ome per microliter of sample (the threshold of
detection). We then compared this ‘time to clear-
ance by PCR’ with the predicted time to clearance
given fS = 0 (in other words, the predicted time to
clearance of the actual infection). The difference in
these times to clearance is reported.
RESULTS
Control mixtures and determination of parasite
density-specific frequency cutoffs
Based on the replicate real-time PCR results, the con-
trol mixture contained 39.13 ng ± 9.18 ng of 7G8
genotype, 30.56 ng ± 2.45 ng of 3D7 genotype and
25.13 ng ± 4.23 ng of Dd2 genotype prior to dilution.
Cloning (n = 22) and sequencing of the PCR product
confirmed that 12/22 (55%), 6/22 (27%) and 4/22
(18%) of the PCR product was 7G8, 3D7 and Dd2,
respectively. The Ion Torrent sequencing results of
the dilution series are shown in Fig. 3.
Total parasite density and read counts for all pa-
tients at all time points are given in Supplementary
Table S1. Supplementary Table S2 lists the haplotype
frequency cutoff used for each of those samples. At a
minimum, we required that a haplotype accounted
for at least 0.5% of the reads in a given sample, a
cutoff that has been used in previous studies [37].
Nine out of 26 samples required higher frequency
cutoffs than this standard.
Determination of haplotypes in longitudinal
samples
Initial sequencing returned 2 514 710 reads corres-
ponding to the C-terminus of pfcsp. After filtering, 1
975 650 (79%) reads were used in our final haplotype
construction. On average, sampled time points had
a read depth of 9685 (range: 203–45 532). After clus-
tering, we determined the total number of unique
pfcsp haplotypes across our patient populations with
10 for Cambodian (7 patients) and 41 for Tanzanian
(19 patients) samples (Accession Numbers:
KR606647-KR606687). All 10 Cambodian haplotypes
were found within the more diverse Tanzanian popu-
lation. The majority of the diversity across haplo-
types is contained within the T-cell epitope regions
of the gene and has been observed previously in
other populations [22, 38]. Across all samples, sin-
gle-nucleotide polymorphisms were observed at
6% of non-epitope sites and 31% of epitope sites.
Looking at the subset of samples from given time
points, we find similar frequencies: at 0 h post-treat-
ment, 5% non-epitope and 31% of epitope sites are
variable; at 72 h, the frequencies are 1% and 26%,
respectively. Overall, we observed very few poten-
tially spurious haplotypes due to accumulation of
random errors across the sequence, and we found
roughly equal numbers at early and late time points.
Such haplotypes would appear as an enrichment of
novel haplotypes that occur in a single sample, given
that the majority of the base positions are invariant.
We observed six single occurrence haplotypes in
early time points (2, 0 and 24 h) and five single
occurrence haplotypes in late time points (48 and
72 h). There was no trend of increasing numbers
with later time points and, in fact, we did not observe
any single occurrence haplotypes at 72 h.
The frequencies of all subpopulations (defined by
the haplotypes) for each patient are given in
Supplementary Table S3. Figure 4a shows how the
relative abundance of different subpopulations
changes over the course of drug treatment for seven
Tanzanian patients who were PCR positive 72 h after
treatment was initiated. Similar plots for 12 add-
itional patients for whom parasites could not be de-
tected at 72 h by PCR can be found in the
Supplementary Material (Supplementary Figs. S2
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and S3). Note that for all Tanzanian patients, para-
sites were undetectable by microscopy 72 h after the
start of treatment. In contrast, all seven Cambodian
patients were microscopy positive 72 h after the start
of treatment; changes in the relative abundance
of subpopulations in these infections are shown in
Fig. 5a.
Figure 6 shows the genetic relationships between
haplotypes observed in one Tanzanian patient, as
well as their relative abundance over time. Each
haplotype found within an individual is highly gen-
etically distant from the other haplotypes within the
same individual, suggesting that these represent
true differences. In the case of patient T40, the haplo-
type that was initially most abundant and cleared
quickly (dark red) differs by eight nucleotides from
the haplotype that was initially rare and cleared most
slowly (green). Note that while total parasite density
in the infection was decreasing, the total size of the
circles in these plots remains constant over time.
(The green haplotype is clearing from the infection
but increases in relative abundance because it clears
at a slower rate.)
K13-propeller domain analysis
Sequencing of the K13-propeller domain of
PF3D7_1343700 showed the presence of the
C580Y mutation associated with artemisinin resist-
ance in all seven Cambodian isolates. The time 0 and
72-h samples from Tanzania were wild type at all
positions across the amplified region, with none of
the polymorphisms described in Cambodia [8], none
previously in the MalariaGen beta release of the P.
falciparum Community Project (http://www.
malariagen.net/apps/pf/2.0/#start) and none previ-
ously described in Africa [10, 11].
Clearance curves of subpopulations
For individual patients, we combined density data
over time with the frequency data to plot
subpopulation-level clearance curves (Fig. 4b) and
compared the fit of two linear models (with and with-
out different slopes for each subpopulation) to these
data to test for variation in clearance rates. In all but
one patient in Tanzania with residual parasitemia 72
h post-drug treatment, we found evidence of signifi-
cant variation in clearance rates between
subpopulations, i.e. the model including multiple
slopes provided a significantly better fit to the data
(Fig. 4b). Identical inferences are drawn if models
are compared using the Akaike Information
Criterion (AIC) instead (Supplementary Table S4).
The best-fit linear models provided good fits to the
data (mean R2 =0.822 ± 0.039 SE). Similar analyses
for 12 patients who were PCR negative 72 h post-
drug treatment revealed significant variability in
clearance rates in eight of those infections as well
(see Supplementary Material and Figs S2 and S3;
mean R2 = 0.879 ± 0.031 SE for all datasets from
Tanzania). That we found significant variation in
clearance rates despite no PCR-detectable parasites
in these infections 72 h after treatment may be due to
lower average parasite densities at the start of treat-
ment (the mean parasite density at the start of treat-
ment ± one standard error of the mean for the
patients who had no detectable parasites at 72 h
was 10 345 ± 3513 and for patients with detectable
parasites at 72 h was 42 689 ± 24 073). There was no
evidence of variation in clearance rates in the pa-
tients from Cambodia. Indeed, most patients har-
bored a single dominant subpopulation for which a
linear curve could be fit to density data (Fig. 5b).
Biological significance of variation in clearance
rates
We simulated infections that capture the relevant
clinical details of each of the six Tanzanian patients
whose infections showed evidence of variation in
clearance rates. We found that modest increases in
the initial frequency of the slowest clearing
subpopulation observed in each case could lead
to large increases in the time to clinical clearance
(Fig. 7). All else being equal, these simulations will
underestimate the change in clearance time: we
compare the predicted clearance time in simulated
infections to the clearance time estimated from fit-
ting a linear curve to the total loge parasite density.
This latter curve represents a weighted average of
the clearance rates of all parasites in an infection,
meaning that the slowest clearing subpopulation is
exerting its phenotypic effect on that estimate of
clearance time. (This is why the predicted difference
in time to clearance is 0 h when the frequency of the
slowest clearing haplotype is 0.)
Figure 8 compares the parasite clearance slopes
estimated from Tanzanian samples with those
estimated from Cambodian samples, where resist-
ance is emerging and where these specific patients
were responding poorly to treatment by standard
measures (microscopy positive at 72 h post-drug
treatment; see also Supplementary Fig. S4).
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Importantly, despite not harboring any of the muta-
tions associated with artemisinin resistance, some
of the subpopulations in Tanzania clear as slowly as
the parasites in Cambodia, which do harbor those
mutations.
DISCUSSION
Standard parasite clearance curves for malaria in-
fections may underestimate the problem of drug
resistance since they are weighted averages of the
clearance phenotypes in an individual and there-
fore struggle to identify resistance when it is rare
[7]. By capitalizing on the wealth of quantitative
data provided by second generation sequencing,
we have developed an approach with the potential
to uncover and track resistance in Africa when it is
rare by estimating the clearance rates of malaria
parasite subpopulations within a given infection.
While we found no evidence of variation in clear-
ance rates within infections in Cambodia, where
multiplicity of infection is quite low and resistance
has already taken hold [2, 4–6], we found evidence
of substantial variation in clearance rates in infec-
tions in Tanzania. The level of variation we observe
is predicted to be important—all else being equal,
small changes in the frequency of the slowest clear-
ing parasites could lead to increases in the clear-
ance time of those infections on the order of days.
Our data suggest that several parasite
subpopulations observed in Tanzania, with no
known K13 resistance-associated mutations, clear
as slowly as parasites in Cambodia, which are
labeled drug resistant and do harbor those muta-
tions. Though quantitative comparisons of clear-
ance rates could be confounded by resistance to
the partner drug (which differed across cohorts),
differences in starting densities or other factors,
clearance slopes in infections in sub-Saharan
Africa are likely to underestimate inherent resist-
ance of parasites due to greater host immunity in
high transmission settings [39]. The data we report
here are consistent with the circulation of rare ar-
temisinin-resistant parasites in Tanzania and
therefore urges further study of identified slow
clearing subpopulations.
It is possible that processes other than drug re-
sistance could result in slower clearance of some
subpopulations within individual infections. Chief
among these is differential selection imposed by im-
mune responses. We have previously argued that the
power of drug selection would overwhelm these ef-
fects [7], especially on timescales as short as one or
two replicative cycles, although recent modeling
work suggests that immunity exerts a large influence
on the clearance of parasites during drug treatment
[40]. The relative contribution of immunity and drugs
toward generating the variation in clearance rates we
observe remains to be determined. This is hard with-
out untreated controls but may be possible with, e.g.
a rodent experimental model. For now, it is worth
noting that drugs exerted little effect on some of the
subpopulations we observed over the timescale
studied. For example, the density of the light green
Figure 3. Deep sequencing of control mixtures. The detected haplotype frequencies of the dilution series are shown, with
parasitemias ranging from three genomic equivalents per microliter (GE/ml) to 1536 GE/ml. Each point represents the mean
(dot) and 1 SD (error bars) of triplicate experiments. Each experiment involves two PCR replicates used to call haplotypes with a
fixed minimum cutoff frequency of 0.5% using SeekDeep. Overall, there is little variation in the frequency estimates within a
concentration and between concentrations. Beginning at 24 GE/ml, false-positive haplotypes begin to be detected. Plotted here is
the sum total frequency of false haplotypes (red line). Individual samples could contain between 1 and 4 false haplotypes, which
individually never exceeded 6% within a single experiment
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Figure 4. Estimating subpopulation clearance curves from infections in Tanzania. (A) Relative abundance of different parasite
subpopulations (defined by haplotypes) within patients. For each patient (row), there are two bar graphs representing technical
replicates, labeled 1 and 2. Within each patient, individual subpopulations have specific colors and are ranked by initial frequency.
(The same color may thus represent different haplotypes in different patients.) (B) Densities of individual subpopulations
(points) are calculated as the total density by quantitative PCR (crosses) multiplied by their relative abundance. Clearance curves
are plotted for the total parasite density (dashed lines) and individual subpopulations (colored lines). Statistics reported rep-
resent model comparisons; P values< 0.05 indicate that a more complicated model that includes different slopes for each
subpopulation within a patient explains significantly more variation than a model with a single slope. Similar plots for 12
additional patients for whom parasites could not be detected at 72 h by PCR can be found in the Supplementary Figs S2 and S3
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Figure 5. Estimating subpopulation clearance curves from infections in Cambodia. (A) Relative abundance of different parasite subpopulations (defined by
haplotypes) within patients. (B) Densities of individual subpopulations (points) are calculated as the total density by PCR (crosses) multiplied by their relative
abundance. Clearance curves are plotted for the total parasite density (dashed lines) and individual subpopulations (colored lines)
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subpopulation in T04 changed only very slightly over
the course of drug treatment (second row in Fig. 4b).
Evading the effects of immunity cannot be the full
explanation for the patterns observed for such
subpopulations; these parasites must also be
evading the effects of drugs. To validate this appar-
ent drug-resistant phenotype, future studies should
identify slow clearing parasites and clone them out
for in vitro assays [9, 21].
Other factors could plausibly affect our estimates
of clearance rates. First, lagged effects of drug treat-
ment [20] could have made our linear fits suspect.
We do not see any evidence of lag phases in our
subpopulation-level data, though these may have
been seen with finer sampling intervals (in which
case, they could be easily excluded [19]). Second,
parasite sequestration or cohort effects could ob-
scure our slope estimates. With sequestration, we
would expect parasite densities to drop and then rise
in consecutive 24-h periods. We might also expect
that the relative abundance of subpopulations
would change if there were multiple cohorts of
parasites sequestering on different days (i.e. with
out-of-phase, 48-h developmental cycles). We find
little evidence of these patterns in Tanzania: total
parasite densities decline in a fairly linear way and
the initially most abundant subpopulation in each
infection is always found at all other time points.
Figure 6. Genetic relationships between parasite haplotypes in one Tanzanian patient. Pseudo minimum spanning tree figure
showing the number of nucleotide differences (red dots) between haplotypes (circles) with the minimum number of mismatches
and their ties shown to include all haplotypes in the graph for patient T40. Haplotypes are colored as in Fig. 3 (second row from the
bottom) and the size of the circle corresponds to the relative abundance of that haplotype at (A) 0 h, (B) 24 h, (C) 48 h and (D) 72 h
after the start of drug treatment. Across time points, the total area of the circles is constant
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Some minor subpopulations do disappear and re-
appear 48 h later (e.g. the tree structures are identi-
cal in Fig. 6a and c, but some nodes are missing in b
and d). Because those subpopulations become un-
detectable and we make no assumptions about
missing data, our slope estimates are unaffected
by the disappearance of minor subpopulations, thus
the changes in relative abundance we observe are
unlikely to be due to sequestration. (Sequestration
might explain the subpopulations that appear only at
72 h post-treatment in Cambodian infections; we do
not believe these to be artifacts as their underlying
haplotypes differ from the predominant variant in
each infection by several base pairs and most match
previously described haplotypes. But again, the ap-
pearance of these subpopulations does not alter our
inferences.) Third, sampling issues leading to
underestimating the density of a subpopulation
early and/or overestimating its density late in infec-
tions would give the impression of slower clearance.
Our approach was conservative in a number of ways
(see Methods) and while parasite densities at 72 h
are low and error in frequency estimates is thus more
likely, it is unlikely that the slower clearing
subpopulations would be systematically
overrepresented only in samples from these later
Figure 7. Predicted effects on clearance time (by PCR) of increasing the initial frequency of the slowest clearing parasite
subpopulation in individual infections. (A) The predicted effects on five of the patients from Tanzania in which significant
variation in clearance rates was observed. One patient is plotted on its own (B) for visibility. (Note that the simulations assume
that all relevant rates remain constant, i.e. there are no changes in pharmacokinetics/pharmacodynamics nor other within-host
processes, over the relevant timescale. This is likely to be violated over the span of 100 days but does not affect our inference of
having detected some very slow clearing subpopulations.)
Figure 8. Comparison of clearance slopes of parasites isolated from patients in Tanzania (patient IDs beginning with T) and
Cambodia (patient IDs beginning with C). For patients from Tanzania, in which significant variation in clearance rates was
observed, the predicted clearance slopes ±1 standard error of individual subpopulations are given in different colors. There was
no significant variation in infections from Cambodia. The dashed lines (shaded region) represent the mean (±1 standard error of
the mean) clearance slopes of patients from each region, as estimated by fitting linear models to the decline in loge total parasite
density
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time points. Further, we quantified and accounted
for changing error rates in the data.
Since the dilution series control experiments sug-
gest that at low parasite density, amplicon deep
sequencing may introduce false haplotypes at low
frequency, we used more stringent frequency cutoffs
in the low parasitemia samples for our analysis.
These haplotypes are unlikely contamination, as
the same DNA is represented in all the dilution ser-
ies samples and the haplotypes did not start to ap-
pear until the low parasitemias. There is nothing to
suggest that these haplotypes should have a com-
petitive advantage during PCR or sequencing as
there are no polymorphisms under the primers, no
length differences in the amplicons and no differ-
ences in the homoploymer runs between haplo-
types. Likely, this represents either mispriming
during the PCR or late PCR errors that make it to
the sequencer as more PCR product is loaded into
the library prep at the low parasitemias. In addition,
it is platform independent, as the same phenom-
enon was observed when the PCR products were
sequenced on an Illumina Miseq (data not shown).
All 72-h Tanzanian samples were wild type at all
K13 positions, with no evidence of mixed peaks on
chromatograph. The subpopulations with a pro-
longed clearance phenotype seen in Tanzania must
therefore have a different mechanism underlying the
slow clearance phenotype. In light of recent evidence
that the genetic background is important for
determining if K13 polymorphisms result in resist-
ance [12, 13], our results support the idea that that
resistance is due to multiple genetic loci. Tanzania
changed its policy on first-line anti-malarial drugs at
the end of 2006 [41]. Our Tanzanian samples were
collected before this time [30] and thus, presumably,
before the parasites within those samples would
have been exposed to significant selective pressure
from artemisinin-based therapies. (Interestingly,
similar levels of variation in clearance times were
recently observed in rodent malaria parasites that
had not previously been exposed to artemisinin
treatment [42].) Given this apparent standing vari-
ation in the absence of drug pressure, we might
therefore have predicted a different underlying gen-
etic mechanism for resistance, which is not unheard
of in falciparum malaria [14]. Further characteriza-
tion of the subpopulations with this phenotype in
Tanzania could lend important insight into the biol-
ogy of artemisinin resistance.
The slow clearing subpopulations we find make up
a large fraction of the parasites in infections 3 days
after drug treatment. Given that patients with such
residual parasitemia have previously been shown to
have higher transmission potential [43], it is reason-
able to predict that the slow clearance we have
observed in Tanzania will lead to increased circula-
tion of slow clearing parasites in the host population.
Why this has yet to occur, despite continued drug
pressure since our samples were collected, may be
a combination of increased parasite genetic diver-
sity and competition within infections, the absence
of permissive parasite genetic backgrounds [12, 13],
low drug coverage and stronger immune responses
altering the overall strength of drug selection in sub-
Saharan Africa. Our data hint at a key role for within-
host competition. The slowest clearance rates we
observed in Tanzania were invariably associated with
subpopulations that were initially rare in infections
(in Fig. 8, the initially rare green and blue haplotypes
have the shallowest slopes while the initially
abundant red and orange subpopulations have the
steepest; see also Supplementary Fig. S5). While this
pattern is also consistent with an immune selection
model (discussed above), it could indicate that more
drug-tolerant strains have a disadvantage within
hosts in the absence of treatment. Moreover, popu-
lation genetic models predict that the effects of any
selection imposed by drugs within a host are likely to
be obscured by selection acting at the between-host
level [44]. If drug-tolerant strains have a competitive
disadvantage in the mosquito, then this will also slow
the spread of these strains in the host population. For
example, tightly linked to the K13 resistance gene is
Pfs47. This polymorphic gene is responsible for eva-
sion of the mosquito immune system and has been
associated with the mosquito species-specific trans-
mission of the parasites [45]. This linkage could limit
the spread of resistance mutations between geo-
graphic regions where the main vector species differs.
While our approach provides finer resolution than
the standard parasite clearance curve on the variation
in clearance phenotypes within an infection, each
subpopulation-level clearance curve we define still rep-
resents a weighted average of that haplotype, which is
likely to be comprised of a number of different parasite
clones. (Indeed, the slow clearing subpopulations we
find in some patients, which are initially rare in those
infections, share haplotypes with initially common and
relatively fast clearing subpopulations in other pa-
tients; see Supplementary Fig. S6). This means that a
resistant clone could still be masked in
a subpopulation by sensitive parasites that share a
haplotype at the sequenced locus. The approach we
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have outlined will thus not be able to identify every low
level and low-frequency resistant parasite that a causa-
tive molecular marker would afford. But our approach
provides finer resolution than the standard parasite
clearance curve on the variation in clearance rates
within an infection and is currently the only one that
can detect this phenotypic signature of resistance in
vivo early in individual, polyclonal infections. Further,
our data from Tanzania highlights the fact that a com-
plete clinical or molecular definition of resistance may
be elusive. The multiplexing approach of using bar-
coded primers keeps sequencing costs per sample at
a relatively modest level (10 dollars a sample for a
study of this size) and the rapid data generation on
small next-generation sequencers, such as the Ion
Torrent or MiSeq, allows for rapid acquisition of data
post-amplification. In the end, our approach can aid
in refining any working molecular definition of resist-
ance by identifying slow clearing subpopulations for
further assessment. Future studies could improve
the power of this approach by using multi-locus haplo-
types or single cell sequencing, which could pro-
vide even finer resolution, and linking this with
association studies to locate causal genetic variation.
For now, our data show that clearance rates for
Plasmodiun falciparum parasites in Africa are highly
variable, a concerning finding for the emergence of
clinically significant resistance to artemisinin.
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